About the Authors
- Renuka Pudi Limgala
-
* E-mail: rlimgala@ldrtc.org
Affiliations Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States of America, Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America
- Chidima Ioanou
-
Affiliation Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States of America
- Matthew Plassmeyer
-
Affiliation Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America
- Mark Ryherd
-
Affiliation Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America
- Lina Kozhaya
-
Affiliation Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America
- Lauren Austin
-
Affiliation Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America
- Cem Abidoglu
-
Affiliation Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America
- Derya Unutmaz
-
Affiliation Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America
- Oral Alpan
-
Affiliation Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America
- Ozlem Goker-Alpan
-
Affiliation Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States of America
Competing Interests
Financial support from Amerimmune, O & O Alpan, LLC in the form of salaries and Sanofi-Genzyme in the form of grant funding do not alter our adherence to all PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: OGA. Formal analysis: RPL LK CA. Funding acquisition: OGA. Investigation: RPL CI MR LK LA CA OGA. Methodology: RPL MP DU OA. Project administration: RPL CI OGA. Resources: MP DU OA OGA. Supervision: RPL DU OGA. Writing – original draft: RPL OGA. Writing – review & editing: DU OA.